Abstract. The aim of this investigation was to identify the domains of type IV collagen participating in cell binding and the cell surface receptor involved. A major cell binding site was found in the trimeric cyanogen bromide-derived fragment CB3, located 100 nm away from the NH: terminus of the molecule, in which the triple-helical conformation is stabilized by interchain disulfide bridges. Cell attachment assays with type IV collagen and CB3 revealed comparable cell binding activities. Antibodies against CB3 inhibited attachment on fragment CB3 completely and on type IV collagen to 80%. The ability to bind cells was strictly conformation dependent.
tetrameric type IV collagen separated by repeated precipitation with 1.7 M NaCI. For further purification, type IV collagen was dissolved in 0.03 M Tris/HC1, pH 8.6, containing 2 M urea and 0.2 M NaCI and applied to DEAE-cellniose (DE52; Whatman Inc., Clifton, N J) in a batch procedure. The nonbinding fraction was dialyzed against 0.1 M acetic acid and lyophilized. All procedures were carried out at 4"C. In type IV collagen samples prepared in this way a part of the methionine residues was oxidized and not available for CNBr cleavage. To minimize oxidation of the methionine residues, fresh placenta was used as starting material for the preparation of type IV collagen, and the procedures described above were carried out under nitrogen to exclude oxygen as far as possible.
Intact type IV collagen from mouse was isolated from the EngelbrethHolm-Swarm tumor by the procedure of Kleinman et al. (26) . The NH2-terminal 7S domain of human type IV collagen was prepared as described earlier (28) . The NC1 domain was isolated from human placenta using a tv~ step collagenase treatment described previously (33) .
Preparation of the CNBr Peptide CB3
Pepsin-derived human type IV collagen was dissolved in 70% formic acid (10 mg/ml), flushed with nitrogen and incubated with CNBr (protein/CNBr 1:1 [wt/wt]) for 4 h at 37°C (13) . Subsequently, CNBr was removed under vacuum overnight; the remaining solution was diluted with 5 volumes of water and lyophilized.
The CNBr-derived peptide mixture was separated on an agarose 1.5 m column (Bio-Rad Laboratories, Richmond, CA) (5 × II0 era) equilibrated with 0.05 M Tris/HCl, pH 7.5, containing 1 M CaC12 and 0.02 M sodium azide at a flow rate of I00 ml/h. The triple-helical, ttimeric CNBr peptide CB3 eluting at a molecular mass range of 80-100 kD was collected and rechromatographed under the same conditions.
Reduction and Carboxymethylation
A solution (5-10 rng/ml) of CB3 in 6 M gnanidine.HCl, 0.05 M Tris/HC1, pH 8.1, and 0.002 M EDTA, was flushed with nitrogen and placed in a 60°C water bath for 30 vain to denature the triple helix. DTT (50 tool per mole disulfide) was added, the tube flushed briefly with nitrogen and maintained at 50°C for 4 h. After cooling the solution to room temperature, an aqueous iodoacetic acid solution (twofold molar excess over DTT) was added. After alkylation for 20 rain in the dark, the reagents were removed by dialysis against 0.1 M acetic acid.
Preparation of Tryptic Fragments of CB3
CB3 was suspended in 0.02 M Tris/HCl, pH 8, at a concentration of 2 mg/ml and heated to 700C for 30 rain to dissolve the protein. To reform the triplehelical structure of the fragment, the solution was kept at 20°C overnight. Trypsin digestion (trypsin-TPCK; Worthington Biochemical Corp., Freehold, NJ) was performed at 200C for 2 h and terminated by adding acetic acid and subsequent lyophilization.
The tryptic digest was first separated on a TSK 3000 SW ultropac cohmm (7.5 x 600mm; Pharmacia-LKB, Uppsala, Sweden), which was equilibrated at a flow rate of 0.15 ml/min with 0.2 M ammonium acetate containing 0.1% trifluoroacetic acid. The fragments pooled were further chromatographed on a Mono Q HR 5/5 (Pharmacia) anion exchanger, using 0.02 M Tris/HC1, pH 8 (solvent A) and 0.02 M Tris/HCl, pHS, 2 M NaC1 (solvent B), both containing 2 M urea, at a flow rate of 0.5 ml/min with a gradient of 2.5-16 % B in 50 min. Fragment 2 was further purified on a Mono S HR 5/5 (Pharmacia) cation exchange column equilibrated with 0.1% trifluoroacetic acid containing 2 M urea, adjusted to pH 2.5 with NaOH (solvent A). Elution was accomplished with 0.1% trifluoroacetic acid, 2 M NaCI, and 2 M urea, pH 2.5 (solvent B), using alinear gradient of 4-25 % B in 30 min at a flow rate of 0.5 ml/min. The pooled fragments were dialyzed against 0.5 M acetic acid.
Analytical Methods
SDS-PAGE followed established protocols (29) . For molecular mass estimates, runs were calibrated with globular proteins (Bio-Rad Laboratories) and CNBr digests of type I collagen, under reducing and nonreducing conditions. For fluorography of gels containing radiolabeled proteins we used Kodak XAR-5 film.
Amino acid compositions and protein concentrations were determined after hydrolysis with 6 M HCI (24 h, ll0*C) on an analyzer (I.~5001; Biotronic Wissensehaft Liche Geriite CsmbH, Puchheim, Germany).
Amino acid sequences were determined by Edman degradation on a gas phase sequencer (model 470A; Applied Biosystems Inc., Foster City, CA) either from purified material or from single protein bands transferred to polyvinylidene difluoride membranes (Immobilon; Millipore Continental Water Systems, Bedford, MA) (31) by semi-dry eleetroblotting with a FastBlot apparatus (Biometra, G6ttingen, Germany) after SDS-PAGE under reducing conditions. The blotting buffer was 50 mM sodium borate at the anode and 50 mM sodium borate with 0.1% SDS at the cathode. Both buffers contained 10% methanol. Blotting was done at 0.8 mA/cm 2 for 1 h.
Immunochemical Methods
Rabbit antisera against CB3 were raised according to standard protocols (43) using 500/~g antigen per injection. The IgG fraction of the serum was isolated by ammonium sulfate precipitation and subsequent chromatography on protein A-Sepharose or DEAE-cellulose (DE 52; Whatman Inc., Clifton, N J). The immunoreactivity of the purified IgG fraction was verified by ELISA.
For the identification of the/~l integrin subunit, the proteins were blotted onto nitrocellulose sheets (Bio-Rad Laboratories) and then immunostained as in reference 46. The antiserum against human/~1 isolated from blood platelets was a gift of Dr. K. vonder Mark, Erlangen, Germany.
Cells and Cell Culture
The following cell lines were used: HTI080 (human fibrosarcoma), A 375 (human melanoma), A 431 (human epidermoid), HBL-100 (human mammary epithelia), SCL I (human skin carcinoma), SCL 11 (human skin carcinoma), Saos-2 (human osteosarcoma), RuGLi (rat glioblastoma), RN22 (rat schwannoma) and primary mouse myoblasts (3, 5) . Cells were grown to coniluency in DMEM, supplemented with glutamine (300/~g/ml), penicillin (400 U/ml), streptomycin (50/zg/ml), and 10% FCS (Gibco Laboratories, Grand Island, NY). For propagation and cell attachment assays, ceils were harvested with 0.05% trypsin, 0.02% ED'I'A in PBS, pH 7.2. For roller bottle cultures (3027; Falcon Labware, Oxnard, CA), 1 mM pyruvate and 15 mM Hepes were used as additional supplements.
Surface Labeling of Cells
108 ceils grown in roller bottles were pelleted and their surfaces labeled with Na 1z5I (37 Megabequerel sp act 481 MBq/~g, Amersham Buchler, GmbH, Braunschweig, Germany) using Iodo-beads iodination reagent (Pierce Chemical Company, Rockford, IL). After labeling, cells were washed three times in TBS, pH 7.2 containing 1 mM each CaC12, MgC12, and MnCI2 (wash buffer).
Attachmen t and Spreading Assays
Attachment assays followed the method described by Aumallley et al. (4) . Tissue culture plates (96 multiwell plates; Costar, Cambridge, MA) were coated by adsorption of the proteins overnight at 4°C. Free binding sites on the plastic were blocked with 1% BSA. The amount of protein adsorbed to the wells was determined in separate experiments by using 125I-labeled protein as tracers and counting the radioactivity after soinbilization with 2 M NaOH. Labeling was performed with iodo-beads (Pierce Chemical Co.) following the manufacturer's instructions. The coating efficiency of CB3 and fragments 1--4 was demonstrated to be comparable to that of intact collagen type IV from human or mouse (3-5 %) .
Freshly suspended cells (see above) in serum-free medium (4 x 105 cells/ml) were plated onto coated wells (0.1 ml/well) and allowed to attach for 30 min at 37°C. For assays carried out in the presence of cycloheximide, this was added to culture dishes 2--4 h before testing, and into the attachment medium at a concentration of 25 pg/mi.
At the end of the attachment period, the medium was removed, the attached cells were washed with medium, fixed in 70% ethanol and stained (41) with 0.1% crystal violet in water (20) . After washing extensively with distilled water, the dye adsorbed to the cells was solubilized with 0.2% Triton X-100 (0.05 ml/well) and optical density was read with an ELISA reader (MR 600; Dynatech; Denkendorf, Germany) at 570 urn. A linear correlation of cell numbers and optical density of released dye has been shown previously (4) .
To assess inhibition of cell attachment by antibodies against CB3, protein coated dishes were incubated with different dilutions of the antibody in PBS for 1 h before adding the cell suspension. Dilutions of the IgG fraction of rabbit nonimmune serum were used as controls, To assess inhibition of cell attachment by synthetic peptides, equal volumes of cell suspensions were mixed with different dilutions of peptides and added immediately to the Proteins were stained with Coomassie brilliant blue. The bands in lanes 4 and 5 were blotted and characterized by Edman degradation. Numbers in brackets denote NHe-and COOH-terminal residues of the individual peptides. Whereas the NH2 termini were directly detected by sequencing, the COOH termini were inferred from the relative molecular mass of the polypeptides and the positions of the methionine residues.
wells (4) . Control experiments contained equal amounts of solvent. The synthetic peptides used were: GRGDS (Protogen AG, L/iufelfingen, Switzerland); ARGDPGF, ARGDP*GF (P* = hydrooxyproline) and SRGDTG (all peptides were synthesized by Dr. J~ger, Martinsried, Germany).
Receptor Extraction from Placenta, Platelets, and Cells
Placenta and platelets were extracted according to (19) with slight modification. Fresh human placenta was freed from chorion and amnion membranes, cut into small pieces and washed in TBS containing 1 mM MnC12, 1 mM PMSE 1 ~tg/ml aprotinin, and 1 t~g/ml antipain by stirring and filtration through a nylon net. The tissue was homogenized in this buffer with an Ultraturax and freed from blood and serum proteins by repeated centrifugation (five times, 1,000 g, 10 min) and resuspension. The insoluble placental material was extracted by adding an equal volume of extraction buffer (washing buffer containing 50 mM octylglucoside) and stirring for 4-6 h at 4°C. After centrifugation at 27000 g for 30 rain, the supernatant was stored at -800C.
Outdated human platelets were washed once with 20 mM Tris/HC1, pH 8, I mM EDTA, 0.9 % glucose, and centrifugation at 1,000 g for 10 rain. The pellet was washed twice with TBS containing 2 mM MgCl2 and protease inhibitors as above by stirring for 1 h at 40C. Finally, the pelleted platelets were extracted with TBS containing 100 mM octylglucoside, 2 mM MgCI2, 1 mM MnCI2, and protease inhibitors. The suspension was centrifuged at 32,000 g for 30 min. The supernatant was stored at -80"C for affinity chromatography.
Trypsinized ceils were collected by centrifugation (200 g, 10 min) and washed three times with TBS containing 2 m_M MgCI2, 1 mM MnCI2, and protease inhibitors as above. After pelleting, ceils were extracted with wash buffer containing 100 mM octylglueoside (1 ml/ml packed cell volume) for 20 min on ice with frequent shaking. Extraction was terminated by centrifugation (16,000 g, 10 min) (19) .
Receptor Isolation by A~inity Chromatography
This is described in reference 19. Peptide CB3 was coupled to CNBractivated Sepharose (Pharmacia LKB, Freiburg, Germany) according to the manufacturer's instructions. The concentration of bound CB3 was 3.5 mg/ml Sepharose. Placental extracts were passed over a CB3-Sepharose column (10 ml bed volume) with a flow rate of 5 ml/h. The column was washed with TBS containing 25 mM octylglucoside, 1 mM MnCI2, and protease inhibitors as above (80 ml) and then with 20 ml of washing buffer containing 300 mM NaC1. Bound protein was eluted with TBS containing 25 mM octylglucoside, 10 mM EDTA and protease irdaibitors. Finally, the column was washed with elution buffer containing 1.85 M NaCI.
Extracts of cells or platelets were incubated with equal volumes of CB3-Sepharose (equilibrated in TBS, 25 mM octylglucoside, 2 mM MgC12, 1 mM MnC12, and protease inhibitors as above) overnight by rotating at 4°C. The Sepharose was then packed into a column (2 x 5 cm) and washed as above. Bound protein was eluted with TBS containing 25 mM octylglucoside and 15 mM EDTA. Eluted samples were made 20 mM in MnCI2 to inactivate EDTA.
Column runs were monitored at 280 run. Aliquots of the collected samples were precipitated by adding 5 vol of acetone (-20"C). After 10 rain precipitates were collected by centrifugation (16,000 g, 10 rain), dried under nitrogen, and dissolved in electrophoresis buffer with or without 8 mM DTT or 200 mM in mercaptoethanol.
Results

Isolation of the Triple-helical Cyanogen Bromide Fragment CB3
As starting material for the isolation of the cell binding site we used pepsin-derived type IV collagen from human placenta. This preparation consists of tetramers in which the molecules are covalently cross-linked via their NH2 terminal 7S domains. They contain intact triple-helical domains. Only the C O O H terminal NC1 domain which was degraded by pepsin is missing (45) . CNBr cleavage of the tetrameric type IV collagen led to a complex peptide mixture which was separated on an Agarose 1.5 m column (not shown). Upon testing individual peptide fractions in cell attachment assays, only one fraction in the range of Mr = 80-100 kD was acfive. SDS-PAGE of this fraction after rechromatography revealed triple-helical C N B r peptides in which the individual o~-chain fragments were held together by disulfide bridges, since several well separated bands appeared after reduction (Fig. 1) . These reduced bands were characterized by blotting and sequencing of the NH2 termini. The trimeric CNBr peptide isolated from tetrameric type IV collagen prepared from fresh placenta under conditions where oxidation of methionine residues was largely prevented (see Materiais and Methods) revealed after reduction the expected monomeric peptides CBed(IV) 291-576 and CBot2(IV) 408-573 (Fig. 2,  Fig. 1, lane 5 ). An additional band between CBotl(IV) and CBoe2(IV) was identified as a COOH-terminal CNBr peptide of the oil(l/I) chain which started at position 789 and had a 220-amino acid residue long triple-helical sequence (2) . It arose from a contamination with type III collagen and could be removed by chromatography on a Mono Q column. This peptide had, in contrast to the entire type III collagen molecule, no cell binding capacity (not shown). The CNBr peptide fraction obtained from tetrameric type IV collagen with partly oxidized methionine residues revealed a peptide mixture (Fig. 1, lanes I and 4) . Beside the expected monomeric peptides, the double peptides CBcxl(IV)291-750, CBal(IV) 233-576, and CBot2(IV)300-573 appeared because of incomplete cleavage due to a fraction of oxidized methionine residues at position 290 and 576 in the or(IV) and 407 in the c~2(IV) chain. For cell attachment experiments only CB3
preparations with a content of <10% of the double peptides were used. Trypsin treatment of CB3 preparations and subsequent chromatography on a TSK 3000 column resulted in four major peaks containing large fragments (Fig. 3 a) . They were further purified by ion exchange chromatography on a Mono Q column (not shown), and then run on SDS-PAGE without and with reduction (Fig. 3 b) . The individual bands observed were blotted and their exact location along the o~l(IV) and c~20V) chain determined by sequence analysis (Fig. 2) .
The Cell Attachment Capacity of the Triple-helical Fragment CB3
Several different cell lines were tested to compare the cell attachment capacity of pepsin-derived type IV collagen and the triple-helical CNBr peptide CB3 (see Materials and Methods). Although the ability to attach to type IV collagen varied among different cell lines, the binding activity to type IV collagen and the peptide CB3 was comparable for any given cell line. No difference could be observed in cell binding between pepsin-derived type IV collagen from human tissue and intact type IV collagen isolated from the Engelbreth-Holm-Swarm mouse tumor (not shown). The experiments carded out with the human fibrosarcoma cells HT1080 are described in detail as an example of the cell lines assayed.
HT1080 cells show almost identical dose-response profiles in their attachment to type IV collagen and peptide CB3 (Fig.  4) . Complete destruction of the triple-helical conformation of CB3 by reduction of disulfde bridges under denaturing conditions and subsequent carboxymethylation abolished cell attachment. Since unfolded collagenous polypeptides crosslinked by covalent bonds easily reform the triple helix, reductive cleavage of the disulfide bridges was essential for complete and irreversible denaturation of CB3 (6, 14) . The two terminal regions of the type IV collagen molecule, the 7S and the NC1 domain did not show cell binding (not shown).
The sequence Arg-Gly-Asp (RGD) is essential for the interaction of extracellular components such as fibronectin and vitronectin with cell receptors of the fll integrin subfamily (23, 36) . Since otl(IV) and ot2(IV) from human type IV collagen contain three and seven RGD sequences, respectively (8, 22) , we used RGD containing synthetic peptides in inhibition assays of HT1080 cell attachment to type IV collagen and CB3. None of the peptides ARGDPGF, ARGDP*GF, SRGDTG, and RGDV, all sequences present in type IV collagen, inhibited cell attachment. Only the peptide GRGDS, a sequence not present in type IV collagen, showed weak inhibitory activity (Fig. 5) . However, at a concentration of 500 #g/ml that inhibited the attachment of HT1080 cells to fibronectin almost completely, still >80 % cell attachment to type IV collagen and CB3 was observed.
Polyclonal antibodies raised against CB3 were used to inhibit cell binding to CB3 and type IV collagen. Under conditions where the attachment of HT1080 cells to CB3 was completely inhibited, type IV collagen still showed a cell attachment corresponding to 20-30 % of the control (Fig. 6) . Since the whole antiserum or IgG purified by DEAE chromatography contained components that appeared to mediate additional cell attachment, only the IgG fraction purified by affinity chromatography on a protein A column could be used for these experiments. Of the four trypsin-derived fragments of CB3, only fragment 1, which comprises almost the entire triple-helical part of CB3 (see Fig. 2 ), showed an attachment capacity similar to CB3 (Fig. 7) . The smallest fragment, fragment 4, with a triple-helical segment from positions 433 to 516 was, however, inactive (Fig. 7) . Extension of the NH2 terminus of this inactive segment to position 408, as in fragment 3, restores the cell binding activity to 80% of the value found for A purified IgG fraction from a rabbit preimmune serum was used as control (u). fragment 1. Fragment 2, in which the inactive segment is extended towards the COOH terminus to position 558 has 40% of the cell binding activity of fragment 1. We also measured the time dependence of cell attachment at a given protein concentration (1 pmol) of CB3 and the trypsin-derived fragments and confirmed the differences in cell binding activity of the trypsin-derived fragments of CB3. The tryptic fragments 1, 2, and 3 did not only promote attachment but also spreading of the HTI080 cells (Fig. 8) . Synthetic peptides representing the sequence of the NH2-terminal triplehelical part of fragment 1 (od(IV) and ot2(IV) positions 408-433 [ Fig. 2] ) were used for cell attachment inhibition experiments. Neither the individual peptides nor the 2:1 mixture of cd(IV) and ct2(IV) peptides showed an inhibition effect with up to 20-fold molar excess over the attachment substrates.
IdenU'fication of CeU Receptors of the lntegrin Family Responsible for the Binding of CeUs to the Fragment CB3
HT1080 and Rugli cells, which attached to and spread to a comparable extent on type IV collagen and CB3, were extracted with an octylglucoside and Mn 2+ containing buffer (19) . The extracts were passed through an affinity column of fragment CB3 immobilized on Sepharose. After washing, the column was eluted with EDTA buffer and the eluates subjected to SDS-PAGE. Both preparations revealed a similar polypeptide with an apparent Mr of 116 kD. After reduction, the molecular mass and decreased electrophoretic mo- The number of ceils was determined as described in the legend to Fig. 4 . The tryptic fragments are described in Fig. 2 .
bility of this band resembled that observed for the integrin subunit/31 ( Fig. 9 a, lanes 5, 6, and 7, 8). In addition, HT1080 and Rugli cell extracts contained a second component of Mr 150 and 190 kD, respectively, resembling in their electrophoresis mobility the integrin subunits at2 and od ( Fig. 9 a, lanes 5, 6 and 7, 8) (27, 36) . In a separate experiment the extract of human HBL-100 cells, surface-labeled with ~25I was applied to a CB3-Sepharose affinity column. The EDTA eluate was submitted to SDS-PAGE. Three bands with relative molecular mass identical to the od, ct2, and/31 subunlts were observed, suggesting the presence of the el/31 and c~2/31 integrins (Fig. 9 b) . The two receptors were also isolated from placenta and blood platelets, and subjected to SDS-PAGE (Fig. 9 a, lanes 1, 2 and 3, 4) . The separated bands were blotted and identified by Edman degradation. The amino-terminal sequences determined for the 190-(FN-VDVKNSMTF) and the 150-kD (YNVGLPEAKIFSGP) band were identical to those of the at1 and t~2 integrin subunits, respectively (24, 40, 41) . Probably due to a blocked NH2 terminus, the 120-kD/31 band did not yield a sequence. The identity of the/31 subunit was therefore proven by Western blot analysis with an antiserum against human/31 (not shown). The/31 subunits isolated from placenta and platelets showed slightly different electrophoretic mobilities (Fig.  9 a, lanes 1, 2 and 3, 4) . This seemed to be due to a different carbohydrate moiety. After deglycosylation they exhibited identical mobility (not shown). Using immobilized, intact murine type IV collagen for affinity chromatography of placenta and platelet extracts, essentially the same results were obtained as with a CB3 column. Except for the integrins al/31 and tx2/31, no additional type IV collagen-binding tritegrins could be observed under the conditions used (not shown).
Discussion
Type IV collagen is responsible not only for the macromolecular organization and the biomechanical stability of basement membranes; along with laminin, nidogen, and heparansulfate proteoglycan it is also involved in the interac- tion of basement membranes with cells (44) . The aim of our investigations was to identify domains of type IV collagen participating in cell binding and the cell surface receptors involved. We found a (150)3 amino acid residue long triplehelical segment, ,~100 nm away from the NH2-terminal end of the molecule, which appears to possess the major cellbinding sites of type IV collagen. Antibodies against CB3, which blocked cell binding of the fragment completely, inhibited cell attachment to type IV collagen up to 80%. The terminal 7S and NC1 domains did not show cell attachment under the experimental conditions used. To what extent other regions of the triple-helical domain of the type IV molecule interact with cells is not clear, since we failed to prepare larger triple-helical segments that did not contain the CB3 region.
Affinity chromatography of cell extracts with the immobilized CB3 fragment was used to identify the cell receptors involved in type IV collagen binding. Two different integrin types, cd/~l and a2/31, were found to interact specifically with CB3. These two integrins are the typical collagen receptors (27, 37, 48) . They mediate cell binding to type I as well as to type IV collagen, and there are reports that at least a2/~l interact also with types 1I, HI and VI collagen (38, 48) . In addition, it has been found that al/~l and a2/~l have affinity for laminin (10, 18, 25) . Thus ligand binding of these two integrins does not appear to be very specific. Whether this is due to a binding domain with an extremely broad specificity or to the presence of several distinct, more specific domains, is not known.
In our experiments, the binding of CB3 to both integrins was strictly dependent on the triple-helical conformation. There are, however, reports that integrins also interact with denatured collagen. This may be due to the fact that the sequence RGD occurs relatively frequently in the triple-helical areas of collagen. After unfolding of the triple helix, RGD sequences become exposed and may then be able to interact with different integrins such as a5/31, ot,/~l, or a~b/~3 ave3, known as RGD-dependent fibronectin or vitronectin receptors (1). However, in intact triple helices the glycine residues, which occupy every third position along the peptide chains, are hidden in the center of the helix and are not accessible for receptors. A typical example is type VI collagen (3). The native molecules with an intact triple-helical domain interact with cells in a RGD-independent manner. The unfolded individual o~ chains of type VI collagen also bind cells, but now cell binding can be inhibited by RGD-containing synthetic peptides. The question is whether interaction of cells with unfolded collagen is physiologically relevant. It can be assumed that in vivo, denatured collagen will be removed by proteolytic enzymes relatively rapidly and that it is present in the extracellular matrix only in negligible amounts. In this respect it is striking that cell attachment to the triple-helical fragment CB3 can be inhibited up to 20 % by 500 #g/rnl synthetic peptide RGDS, in spite of the fact that it does not contain a RGD sequence. Thus inhibition of cell attachment in the presence of high amounts of RGD containing synthetic peptides may lead to unspecific results.
Cell binding to the four trypsin derived fragments of CB3 revealed two sequence regions important for binding the a2~l containing HT1080 cells ,,o50 ran away from each other, whereby the NH2-terminal site appeared to be the more important one. Experiments with isolated integrins will be necessary to decide whether a2/31 interacts with two neighboring triple-helical segments or whether additional collagen binding proteins at the surface of the HTI080 cells are involved. Synthetic peptides with the od(IV) and a2(IV) sequences of the NHz-terminal cell binding site of CB3 did not show any binding or inhibitory effect, neither in large molar excess, nor in mixtures. This corroborates our finding that the activity to interact with cells is strongly dependent on the triple-helical structure and that both polypeptide chains are important constituents of the binding site.
Recently it has been reported (9) that a synthetic peptide of 15 amino acid residues, representing an al0V) sequence located near the COOH-terminal end of the triple-helical domain of the type IV collagen molecule, promoted adhesion and spreading of a murine melanoma cell. Another synthetic peptide with a sequence of al(IV) in the vicinity of the CB3 fragment seemed to promote attachment of human keratinocytes (50) . In both cases the cell receptors are unknown. Staatz et al. (39) have observed that the a2/~l integrin, which is responsible for the Mg+2-dependent adhesion of platelets to type I collagen, interacts not only with the triple-helical type I collagen molecule, but also with the unfolded cd(I) and a2(I) chains and the 147-residues long CNBr peptide al(I)CB3. In earlier experiments (16) it was shown that adhesion of platelets to type I and HI collagen depends on the triple-helical conformation. Only one CNBr peptide of type HI collagen, ,10II)CB4, in location and sequence homologous to al(I)CB3, also revealed platelet adhesion activity, but in comparison to the activity of the triple-helical molecule only in a 500-1,000-fold molar excess. Comparison of the sequences of al(I)CB3 and od(III)CB4 with the amino acid sequence of the ,10V) and a20N) chains of fragment CB3 did not reveal an obvious homology.
The question arises whether the cell binding site of the CB3 region, discovered in soluble collagen molecules is also accessible to cells in type IV collagen when it is incorporated in the extracellular matrix. There is evidence that the CB3 region is accessible in tissue. Treatment of human placenta and murine Engelbreth-Holm-Swarm tumor tissue with bacterial collagenase at 20°C cleaves the type IV collagen molecule only at one site in the NH2-terminal vicinity of the cell binding site in CB3 (49) . In mouse type IV collagen the initial cut occurs between Pro (390) and Gly (391) (Mann, K., A. Ries, and K. Kiihn, unpublished results). Similar collagenase treatment of dissolved type IV collagen molecules causes additional cleavages at several other regions of the triple-belical domain. It is interesting that the cleavage site of the mammalian metalloproteinase collagenase IV is also located close to the NH2-terminal area of CB3 (17) .
The close proximity of the cell binding site as well as the cleavage site of collagenase IV may be used by invading tumor cells to penetrate basement membranes. Having attached to the collagen network via the cell binding site of CB3, the tumor cells secrete type IV collagenase which hydrolyzes type IV collagen in the CB3 area (11, 42) . This could result in the destruction of the cell binding site as well as produce local degradation of the collagen IV network whereupon the cells detach themselves from type IV collagen and penetrate basement membranes at the sites of proteolysis.
The isolation of a relatively short and stable triple-helical segment, which bears the binding site for the typical collagen receptors cdB1 and o~2B1, provides for the first time the opportunity to investigate in more detail those regions of the od, c~2, and B1 subunits of integrins which are responsible for the interaction with a stiff, rod-like collagen ligand.
